No Data
No Data
No Data
No Data
No Data
Insiders Of INmune Bio Are Up 38% On Their US$714.9k Purchase
INmune Bio, Inc. (NASDAQ:INMB) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 35%, resulting in a US$61m rise in the company's market capitalisation,
Simply Wall StApr 27 09:26 ET
Express News | INmune Bio Says Remains On Track In Line With Prior Guidance To Complete Its Phase 2 Clinical Trial Involving The Use Of XPro For The Treatment Of Alzheimer's Disease In Patients With Biomarkers Of Neuroinflammation
BenzingaApr 25 16:56 ET
Inmune Bio Earns Buy Rating on Positive XPro Developments and Strong Financials
TipRanksApr 25 12:55 ET
Express News | INmune Bio Announces $9.7M Registered Direct Offering Of 986,000 Shares And Warrants At $9.84/Share And Accompanying Warrant
BenzingaApr 25 09:01 ET
Express News | INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
ReutersApr 25 09:00 ET
(SEC Amendment) INmune Bio(INMB.US) 10% Shareholder Buys US$149.99K in Common Stock
$INmune Bio(INMB.US)$ 10% Shareholder Tesi Raymond Joseph purchased 18,028 shares of common stock on Apr 19, 2024 at an average price of $8.32 for a total value of $149.99K. This transaction involves
moomoo NewsApr 24 14:52 ET
Sarcasmoblaster : Anything is better than SAVA these days
No Data
No Data